High-Grade Malignant Immunoblastic Lymphoma



Immunoblastic lymphoma (IBL), also known as diffuse histiocytic lymphoma, is a malignant disorder of the B cell (see the image below). Although this condition was initially considered a more aggressive variety of lymphoma with a poor prognosis when compared with diffuse large-cell non-Hodgkin lymphoma (DLCL), newer combination chemotherapeutic approaches yield an overall survival rate in immunoblastic lymphoma that is similar to the rate in DLCL.

View Image

Lymph node biopsy (hematoxylin and eosin stain) showing diffuse involvement with loss of architecture in a patient with immunoblastic non-Hodgkin lymp....

Immunoblastic lymphoma is a fatal disease if untreated and is potentially curable with intensive chemotherapy. The success of treatment depends on the extent of disease at the time of presentation, associated B symptoms, initial therapeutic choice, and response to therapy.

The frequency rate in the United States is approximately 9% of all non-Hodgkin lymphomas. Of these, 70% are of B-cell origin and 25% are of T-cell origin.

No difference exists among races or between the sexes. However, although immunoblastic lymphoma can appear in persons of any age, it presents most commonly in persons who are middle-aged or older, and it is commonly observed in patients of any age who are immunocompromised.

Go to Non-Hodgkin Lymphoma for a complete discussion of this topic.


The World Health Organization (WHO) consensus classification should replace all existing classifications. The WHO classification of hematologic malignancies uses an updated version of the Revised European-American Lymphoma (REAL) classification for lymphoid neoplasms.[1, 2, 3]

Earlier classifications subdivided diffuse large B-cell lymphomas (DLBCLs) either by morphology or by the biologic behavior. Kiel's classification subdivides large B-cell lymphoma into immunoblastic and centroblastic lymphomas. In the Working Formulation, immunoblastic lymphoma is classified with lymphoblastic lymphoma and small noncleaved-cell lymphoma as a high-grade non-Hodgkin lymphoma (NHL). The International Lymphoma Study group uses all available information, morphology, immunophenotype, genetic features, and clinical features, to define a disease entity.

Etiology and Pathophysiology

Causes of immunoblastic lymphoma include the following:

Immunoblastic lymphoma can originally derive from B or T cells. The Working Formulation differentiates subtypes of immunoblastic lymphoma by cell of origin.[5] The subtypes include plasmacytoid, clear cell, polymorphous, and epithelial cell component. From a clinical point of view, this subclassification has little value; B- or T-cell origin cannot be predicted based on morphology.[6]

In the Revised European-American Lymphoma (REAL) classification, except in morphologic descriptions, the schema includes immunologic, cytogenetic, and molecular information in order to define distinct lymphoma entities.[7] The diffuse large B-cell lymphomas (DLBCLs) are considered in the REAL classification as the classic diffuse large-cell non-Hodgkin lymphoma (DLCL) of B-cell origin defined by the Working Formulation.

Clinical Evaluation

Most patients with immunoblastic lymphoma present with advanced disease; only as few as 30% present with limited-stage disease (I or II). Symptoms vary and depend on the site of involvement.

Painless lymphadenopathy is the most common presenting feature of immunoblastic lymphoma. Occasionally, pain might be associated with aggressive tumor growth. Adenopathy is usually marked and may involve any site; often, it is generalized.

B symptoms may be present. Patients report profuse night sweats, fever is usually low grade (range 100-101°F), and patients may report unintentional weight loss of more than 10% in 6 months. Other symptoms may include fatigue (anemia) and neurologic deficit (central nervous system [CNS] involvement).

Physical examination findings may include the following:


The Ann Arbor Staging Classification designed for Hodgkin disease is now used (with certain limitations) for non-Hodgkin lymphoma (NHL) classification. This classification, outlined below, does not recognize disease of bulk, which has prognostic and therapeutic importance.

Differential Diagnosis

The following conditions are considered a part of the differential diagnosis of high-grade immunoblastic lymphoma:

Laboratory Evaluation

Obtain a complete blood cell (CBC) count and peripheral blood smear, as well as serum chemistry levels, including lactate dehydrogenase (LDH) and serum electrolytes. Other laboratory studies should include liver and renal function tests.

Elevated beta-2 microglobulin levels are associated with a poor prognosis.

Obtain a coagulation profile before any surgical intervention (eg, tissue biopsy, placement of a venous access port).

Serum protein electrophoresis is rarely performed; however, this may show the presence of monoclonal proteins or an increase in immunoglobulins.

Cytogenetic Studies

Cytogenic studies are generally used to help exclude other types of non-Hodgkin lymphoma (NHL). Chromosomal aberrations, such as del(6q),+X, are associated with immunoblastic lymphoma, but they are not exclusive for this type. Mutations or allelic losses of the p53 tumor suppressor gene are common in the immunoblastic type.

Yunis et al observed that rearrangement of BCL2 in patients with immunoblastic lymphoma correlates with poor response to therapy.[8]

Immunoblastic lymphoma morphology is characterized by MUM1 expression and infrequent bcl6 expression.

Radiography, CT Scanning, and MRI

Chest radiographs are used for staging purposes.

Computed tomography (CT) scanning of the chest, abdomen, and pelvis to evaluate nodal and extranodal involvement is also usually part of the staging workup. CT scanning of the head is performed only if neurologic symptoms are present.

Magnetic resonance imaging (MRI) of the spine and brain may be performed for patients with a paraspinal mass to assess for epidural involvement and cord compression. Patients with signs or symptoms suggestive of intracranial disease may also require an MRI.

Nuclear Imaging

Most of the studies evaluating positron emission tomography (PET) scanning results were performed mainly in cases of diffuse large-cell non-Hodgkin lymphoma (DLCL). PET scans may be more sensitive compared with other imaging modalities, including gallium, when used for lymphoma staging.

Although a nonspecific test, a gallium scan is often useful in follow-up evaluations for patients with initial gallium-avid disease. Therefore, gallium scanning is performed as part of the initial staging workup. Clinical correlation with computed tomography (CT) scan results is always recommended in patients with abnormal gallium scan results.

Bone scanning should be performed only if the patient has unexplained bone pain and a high alkaline phosphatase level.

Multigated angiogram (MUGA) scanning is usually performed to assess the cardiac ejection fraction before starting potentially cardiotoxic chemotherapy.


Bilateral iliac crest bone marrow biopsy and aspiration is performed as part of the staging evaluation. Excisional lymph node biopsy is preferred over fine-needle aspiration in patients with suspected lymphoma. Adequate tissue should be obtained for histopathologic and flow cytometric examination.

Skin biopsy may be indicated, although rarely, if lesions suggestive of cutaneous involvement are present.

Lumbar Puncture

Lumbar puncture and cerebrospinal fluid (CSF) examination are warranted in patients with THE following:


Preferably, an experienced hematopathologist should review pathology findings.

Immunoblastic lymphomas have varying morphologic characteristics, ranging from plasmacytoid features to more pleomorphic characteristics. Generally, they comprise immunoblasts (>90%), with centrally located nucleoli, and centroblasts (must be < 10%) (see the following image).

View Image

Lymph node biopsy (hematoxylin and eosin stain) showing diffuse involvement with loss of architecture in a patient with immunoblastic non-Hodgkin lymp....

Treatment Overview

As discussed earlier, immunoblastic lymphoma is classified as an intermediate-grade non-Hodgkin lymphoma (NHL) and is treated using therapeutic guidelines similar to those used for diffuse large-cell non-Hodgkin lymphoma (DLCL).

Non-Hodgkin lymphoma is treated with chemotherapy, with or without radiation.

The current standard of treatment for immunoblastic lymphoma is combined-modality treatment in the limited stage and chemotherapy only in the advanced stage. CHOP+R regimen (cyclophosphamide, hydroxydaunomycin [doxorubicin], Oncovin [vincristine], prednisone, and rituximab) is the therapy of choice.[9, 10] All other chemotherapeutic regimens are used as salvage treatment.

Patients can be further subclassified as having bulky or nonbulky disease and low, intermediate, or high risk based on the International Prognostic Index (see Prognosis and Prognostic Factors).

Surgical procedures are limited to diagnostic or palliative purposes or for placement of an indwelling central venous catheter.

Admission and transfer

Admit patients for chemotherapy-related toxicity or febrile neutropenia. In addition, those patients who may require high-dose chemotherapy (HDC) and autologous bone marrow transplant (ABMT) require inpatient care until their counts recover, and engraftment is achieved posttransplantation.

Patients may require transfers in following situations:


Antibiotics may be needed in episodes of fever postchemotherapy. The choice of antibiotics is usually based on the clinical presentation and clinical findings upon presentation. In cases in which no identifying source is found, broad-spectrum coverage should be started empirically. Most patients require hospitalization and intravenous administration of antibiotics.

Antiemetic agents are usually prescribed for both acute and delayed onset of nausea and vomiting.

In the hospital, intravenous hydration may be warranted in patients with a high tumor burden who are at high risk for tumor lysis syndrome. Allopurinol is usually started in patients with a high tumor burden to prevent tumor lysis syndrome.


The following consultations may be needed during the course of treatment:

Limited Stage I and II Disease

In patients with nonbulky disease and no adverse risk factors, use the cyclophosphamide, hydroxydaunomycin, Oncovin (vincristine), prednisone, and rituximab (CHOP+R) chemotherapy regimen for 3-4 cycles and involved-field radiation therapy (IFRT).[11]

In patients with bulky disease (tumor >10 cm in the greatest dimension) and the presence of an adverse risk factor, use the CHOP+R chemotherapy regimen for 6-8 cycles and involved-field radiation therapy.

In a randomized study by Ennishi et al, CHOP+R therapy (rituximab administered on day 1 of CHOP) emerged to become the standard initial treatment for diffuse large B-cell lymphoma (DLBCL) in the United States.[12]

The benefit of irradiation is still controversial. Chemotherapy followed by consolidation radiotherapy has a 5-year overall survival rate and progression-free survival rates of up to 80%. Rituximab-based chemotherapy and the observation that radiation does not improve overall survival incline for chemotherapy alone.[13]

Advanced Stage III and IV Disease

In patients with low-intermediate risk, use 6-8 cycles of the cyclophosphamide, hydroxydaunomycin, Oncovin (vincristine), prednisone, and rituximab (CHOP+R) chemotherapy regimen.

In individuals with high-intermediate or high risk, use 6-8 cycles of the CHOP+R chemotherapy regimen or offer enrollment in a clinical trial.

High-Dose Chemotherapy and ASCT

Patients with primary resistant or relapsed disease who show some chemosensitivity with second-line salvage therapy should be considered for high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT).[14, 15]

Current recommendations are to carefully consider HDC and ASCT for patients in their first relapse, after chemoresponsiveness is established with a second-line salvage therapy. However, the role of HDC plus ASCT in first complete remission for patients who have a slow initial response to front-line chemotherapy, those with poor initial prognostic factors, or as up-front therapy has not been clearly defined and remains controversial.

Salvage Regimens

For primary resistant or refractory cases, the dexamethasone, cisplatin, and cytarabine (DHAP) regimen may be used. Alternatively, consider using the etoposide, methylprednisolone, cisplatin, and cytarabine (ESHAP) regimen. Finally, consider using the methotrexate,[16] bleomycin, Adriamycin (doxorubicin), cyclophosphamide, Oncovin, and dexamethasone (M-BACOD) regimen every 3 weeks.

Follow-Up Monitoring

While on chemotherapy, patients should be monitored very carefully, including complete blood cell (CBC) counts and serum chemistry evaluations. Elderly patients may require home health services, because chemotherapy may compromise their performance status.

Follow up periodically with patients whose condition responds to chemotherapy and who achieve a complete response. Those who have a partial remission should either be treated with a new non–cross-resistant chemotherapy regimen or be considered for the best supportive care.

Patients with indwelling catheters may require daily heparin flushes to prevent clotting.

Growth factors may be required in patients with neutropenia or anemia, such as granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF), or recombinant erythropoietin. These are administered subcutaneously and can usually be administered by the patients themselves in an outpatient setting.

For patients who develop severe anemia or thrombocytopenia as a result of chemotherapy, outpatient transfusions may be required.

For patients with concomitant diabetes mellitus, home monitoring of blood glucose may be required while they undergoing chemotherapy, because these patients often develop electrolyte imbalances from nausea/vomiting or hyperglycemia from steroids, which are administered as part of the chemotherapy regimen (eg, cyclophosphamide, hydroxydaunomycin, Oncovin [vincristine], prednisone, and rituximab [CHOP+R]).

Posttreatment periodic follow-up evaluation is essential in these patients, because a substantial number of patients may relapse, especially those categorized as intermediate-high risk or high risk. A complete physical examination, CBC count, and computed tomography (CT) scans are initially performed every 3 months for the first year; the frequency can then be decreased to every 4-6 months depending on the initial risk category of the lymphoma.


Neutropenic fever, opportunistic infections, and tumor lysis syndrome (ie, hyperuricemia, hyperkalemia, hyperphosphatemia) are all possible complications of immunoblastic lymphoma.

In many cases, even if treated properly, neutropenic fever can be fatal. Shortening the neutropenic phase with cytokines and early induction of prophylactic antibiotics is helpful.

Recognizing the patients who are at risk of tumor lysis syndrome (high uric acid level, high tumor burden) is important. Before chemotherapy, allopurinol, intravenous hydration, and urine alkalization should be started. Renal function should be monitored carefully.

Neutropenia and/or anemia may result from the disease or its treatment. Growth factors (eg, recombinant erythropoietin, interleukin 11 [IL-11], granulocyte-macrophage-colony-stimulating factor [GM-CSF], granulocyte-colony-stimulating factor [G-CSF]) may be indicated in some patients to promote bone marrow proliferation and blood cell production.

Prognosis and Prognostic Factors

Patients undergoing combination chemotherapy may experience long-term morbidity primarily associated with the chemotherapeutic agents.

International Prognostic Index

The International Prognostic Index (IPI) is commonly used to assess the prognosis of aggressive non-Hodgkin lymphoma (NHL).[17, 18] This was established by the International Non-Hodgkin's Lymphoma Prognostic Factors Project as a predictive model for patients with NHL based on 5 adverse pretreatment characteristics, as follows[18] :

From the evaluation of the 5 characteristics, patients are classified into 4 categories, as follows:

Based on these pretreatment risk factors, the complete remission (CR) rate is 87% and the 5-year overall survival rate is 73% for patients who are at low risk compared to 44% and 26%, respectively, in the high-risk group.

Skp2 and p27 as prognostic markers

Seki et al reported there is a significant correlation between poor overall survival and the presence of either high Skp2 expression or low p27 expression; the worst survival rate occurred in their patients with a combination of high Skp2 expression and low p27 expression.[13] The investigators examined the efficacy of CHOP+R therapy in patients with high expression of S-phase kinase-associated protein 2, or Skp2, and/or low expression of cyclin-dependent kinase inhibitor p27(kip1). (Previous evidence has pointed to a role for Skp2 not only in carcinogenesis but also in lymphomagenesis.) Of 671 patients, 425 were treated with CHOP patients and 246 received CHOP+R (246 patients). Due to the correlation of Skp2 and p27 in both treatment groups, Seki et al suggested that, with regard to rituximab treatment, Skp2 and p27 may be useful as prognostic markers.[13]

Patient Education

Patients should receive information about the following:

Sterile technique should be emphasized in patients who are prescribed growth factors postchemotherapy at home.

Patients with indwelling catheters should be instructed about daily heparin flushes under aseptic conditions to prevent clotting. Also discuss possible catheter-related complications.

In most instances, no special activity restrictions are required. Special circumstances may require some intervention.

Patients with neutropenia

Patients with neutropenia should follow a neutropenic diet; that is, avoid undercooked meat, and fruits and vegetables should be either cooked or peeled.

All personnel and visitors of neutropenic patients should wash their hands. Neutropenic individuals should avoid contact with persons known to have ongoing viral or bacterial infections, as well as avoid potted plants and flowers, because these may be a source of fungal spores.

Adequately educate patients regarding neutropenic fevers, and emphasize seeking early medical attention in case of fever that may develop postchemotherapy.

Patients with thrombocytopenia

Thrombocytopenic patients should pay special attention to oral hygiene, including frequent rinsing and brushing of teeth only with a toothette sponge. These individuals should also take precautions to avoid falls and to avoid strenuous physical activity.

For patient education information, see Blood and Lymphatic System Center, as well as Lymphoma.

Special Considerations

Potential medicolegal pitfalls include the following:


Asher A Chanan-Khan, MD, Assistant Professor, Department of Medicine, Division of Lymphoma and Bone Marrow Transplantation, Roswell Park Cancer Institute, State University of New York at Buffalo

Disclosure: Nothing to disclose.

Specialty Editors

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Chief Editor

Emmanuel C Besa, MD, Professor Emeritus, Department of Medicine, Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Kimmel Cancer Center, Jefferson Medical College of Thomas Jefferson University

Disclosure: Nothing to disclose.

Additional Contributors

Paul Schick, MD, Emeritus Professor, Department of Internal Medicine, Jefferson Medical College of Thomas Jefferson University; Research Professor, Department of Internal Medicine, Drexel University College of Medicine; Adjunct Professor of Medicine, Lankenau Hospital

Disclosure: Nothing to disclose.


The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous author Beata Holkova, MD, to the development and writing of the source article.


  1. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting--Airlie House, Virginia, November, 1997. Hematol J. 2000. 1(1):53-66. [View Abstract]
  2. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994 Sep 1. 84(5):1361-92. [View Abstract]
  3. Skarin AT, Dorfman DM. Non-Hodgkin's lymphomas: current classification and management. CA Cancer J Clin. 1997 Nov-Dec. 47(6):351-72. [View Abstract]
  4. Corti M, Villafañe MF, Bistmans A, Campitelli A, Narbaitz M. Soft-tissue masses as presentation of non-Hodgkin's lymphoma in AIDS patients. An Bras Dermatol. 2013 Aug. 88(4):631-4. [View Abstract]
  5. De Paepe P, Achten R, Verhoef G, Wlodarska I, Stul M, Vanhentenrijk V, et al. Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas. J Clin Oncol. 2005 Oct 1. 23(28):7060-8. [View Abstract]
  6. Xue Y, Wang Q, He X. Clear cell variant of diffuse large B-cell lymphoma: a case report and review of the literature. Int J Clin Exp Pathol. 2015. 8 (6):7594-9. [View Abstract]
  7. Vose JM. Molecular pathogenesis in non-Hodgkin lymphoma: Implications for therapy. Transfus Apher Sci. 2013 Sep 16. [View Abstract]
  8. Yunis JJ, Mayer MG, Arnesen MA, Aeppli DP, Oken MM, Frizzera G. bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma. N Engl J Med. 1989 Apr 20. 320(16):1047-54. [View Abstract]
  9. Held G, Zeynalova S, Murawski N, Ziepert M, Kempf B, Viardot A, et al. Impact of Rituximab and Radiotherapy on Outcome of Patients With Aggressive B-Cell Lymphoma and Skeletal Involvement. J Clin Oncol. 2013 Sep 23. [View Abstract]
  10. Wu JZ, Min K, Fan L, Wang L, Xu J, Li JY, et al. Plasmablastic lymphoma following combination treatment with fludarabine and rituximab for nongastric mucosa-associated lymphoid tissue lymphoma: a case report and review of literature. Int J Clin Exp Pathol. 2014. 7 (7):4400-7. [View Abstract]
  11. Tondini C, Zanini M, Lombardi F, Bengala C, Rocca A, Giardini R, et al. Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non-Hodgkin's lymphomas. J Clin Oncol. 1993 Apr. 11(4):720-5. [View Abstract]
  12. Ennishi D, Asai H, Maeda Y, Shinagawa K, Ikeda K, Yokoyama M, et al. Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ann Oncol. 2010 Jun. 21(6):1217-21. [View Abstract]
  13. Seki R, Ohshima K, Fujisaki T, Uike N, Kawano F, Gondo H, et al. Prognostic significance of S-phase kinase-associated protein 2 and p27kip1 in patients with diffuse large B-cell lymphoma: effects of rituximab. Ann Oncol. 2010 Apr. 21(4):833-41. [View Abstract]
  14. Dean RM, Bishop MR. Allogeneic hematopoietic stem cell transplantation for lymphoma. Clin Lymphoma. 2004 Mar. 4(4):238-49. [View Abstract]
  15. Vose JM, Zhang MJ, Rowlings PA, Lazarus HM, Bolwell BJ, Freytes CO, et al. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol. 2001 Jan 15. 19(2):406-13. [View Abstract]
  16. Hsiao SC, Ichinohasama R, Lin SH, Liao YL, Chang ST, Cho CY, et al. EBV-associated diffuse large B-cell lymphoma in a psoriatic treated with methotrexate. Pathol Res Pract. 2009. 205(1):43-9. [View Abstract]
  17. Bernd HW, Ziepert M, Thorns C, Klapper W, Wacker HH, Hummel M, et al. Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials. Haematologica. 2009 Nov. 94(11):1569-80. [View Abstract]
  18. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993 Sep 30. 329(14):987-94. [View Abstract]

Lymph node biopsy (hematoxylin and eosin stain) showing diffuse involvement with loss of architecture in a patient with immunoblastic non-Hodgkin lymphoma (NHL).

Lymph node biopsy (hematoxylin and eosin stain) showing diffuse involvement with loss of architecture in a patient with immunoblastic non-Hodgkin lymphoma (NHL).

Lymph node biopsy (hematoxylin and eosin stain) showing diffuse involvement with loss of architecture in a patient with immunoblastic non-Hodgkin lymphoma (NHL).